Keryx Biopharmaceuticals (NASDAQ:KERX)‘s stock had its “hold” rating reaffirmed by equities research analysts at Stifel Nicolaus in a research note issued on Monday. They presently have a $5.00 price objective on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective suggests a potential upside of 1.63% from the company’s current price.
A number of other equities analysts have also issued reports on the company. BidaskClub lowered Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, March 20th. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, April 11th. Maxim Group set a $9.00 target price on Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 10th. Finally, ValuEngine raised Keryx Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $7.19.
Shares of Keryx Biopharmaceuticals opened at $4.92 on Monday, Marketbeat.com reports. The firm has a market capitalization of $590.58 million, a P/E ratio of -5.59 and a beta of 2.63. The company has a quick ratio of 1.87, a current ratio of 2.66 and a debt-to-equity ratio of -3.96. Keryx Biopharmaceuticals has a 1 year low of $3.92 and a 1 year high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Friday, May 11th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.18). The company had revenue of $21.75 million during the quarter, compared to analyst estimates of $21.80 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 230.00%. analysts forecast that Keryx Biopharmaceuticals will post -0.56 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in KERX. Schwab Charles Investment Management Inc. grew its position in Keryx Biopharmaceuticals by 4.7% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 519,331 shares of the biopharmaceutical company’s stock worth $2,415,000 after purchasing an additional 23,435 shares during the period. Teacher Retirement System of Texas acquired a new stake in Keryx Biopharmaceuticals during the 4th quarter worth about $142,000. First Trust Advisors LP acquired a new stake in Keryx Biopharmaceuticals during the 4th quarter worth about $749,000. BlackRock Inc. grew its position in Keryx Biopharmaceuticals by 1.9% during the 4th quarter. BlackRock Inc. now owns 6,097,948 shares of the biopharmaceutical company’s stock worth $28,356,000 after purchasing an additional 112,381 shares during the period. Finally, Geode Capital Management LLC grew its position in Keryx Biopharmaceuticals by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 912,179 shares of the biopharmaceutical company’s stock worth $4,241,000 after purchasing an additional 19,003 shares during the period. 61.60% of the stock is currently owned by institutional investors.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.